



SHSA 2020 Virtual Program – at a Glance

Times are noted in Eastern Daylight Time (EDT)

As at September 25, 2020

Overall Learning Objectives
1. To highlight the current research ranging from the burden of the disease to the new treatment
2. To discuss the latest innovations, discoveries and new treatment modalities related to HS
3. To discuss experiences and unmet needs regarding HS research and management

Friday, October 9		
9:00am - 5:00 pm	Visit Sponsor Exhibit Profiles View Poster Presentations Review the SHSA Abstract Book Connect with fellow SHSA Attendees	
12:00-2:00pm	Advisory Board: AbbVie	<i>By invitation only</i>
12:00pm - 1:00pm	Chat room: Patient/Caregiver: Welcome	Moderators: <i>Michelle Lowes, Joslyn Kirby</i>
12:00pm - 2:00pm	Sponsor Exhibit Profiles - visit the booth profile and meet your reps	
2:00 pm - 3:00 pm	Chat Room: HS Progress An overview of HS PROGRESS and status update for all attendees	Moderators: <i>Michelle Lowes, Haley Naik</i>
3:00pm - 4:00pm	Satellite Symposium: Appulse Medical	<i>All attendees invited to this session</i>
4:00pm - 5:00pm	Exhibit Hall - visit the booth and meet your reps	
4:00pm - 5:00 pm	Chat Room: Mentorship - become an HS Expert For anyone with an interest in becoming a mentor	Moderators: <i>Steven Daveluy, Stephanie Goldberg</i>
4:00pm - 5:00pm	Chat room: Patient/Caregiver: Finding Great HS Care	Moderator: <i>Sandra Guilbault</i>

Saturday, October 10		
9:00am - 5:00 pm	Visit Sponsor Exhibit Profiles View Poster Presentations Review the SHSA Abstract Book Connect with fellow SHSA Attendees	
9:00am - 10:00	Chat Room: Patient/Caregiver: Comorbidities of HS	<i>Moderators: Raed Alhusayen, Isabelle Delorme</i>
9:00 am - 10:00 am	Sponsor Exhibit Profiles - visit the booth profile and meet your reps	
10:00am-12:00pm	Session 1: Health Services & Epidemiology	<i>Moderator: Joslyn Kirby</i>
Session Learning Objectives:		
1. To describe recent data related to the epidemiology and burden of HS		
2. To discuss HS Covid registry findings		
3. To review research funding opportunities for HS		
10:00	NIAMS Update	<i>Ricardo Cibotti</i>
10:10	Making the most out of visits with HS patients	<i>Chris Sayed</i>
10:30	COVID19 Registry Discussion	<i>Haley Naik</i>
10:50	Provider perspectives and practice patterns on the management of hidradenitis suppurativa in pregnancy	<i>Jennifer Hsiao</i>
10:58	Comorbidity screening in HS: evidence-based recommendations from the US and Canadian HSFs	<i>Amit Garg</i>
11:06	Outcomes of Pregnancy, Childbirth, and Puerperium	<i>Surav M. Sakya</i>
11:14	Pregnancy in HS: Patient perspectives and practice gaps	<i>Natalie M. Villa</i>
11:22	Pain severity and management of HS at Emergency Department Visits in the US	<i>Matthew T. Taylor</i>
11:30	Live Panel Q&A	<i>All Presenters</i>
12:00 - 12:30 pm	Chat Room: Patient/Caregiver: Treatment of HS - medicines and integrative	<i>Moderators: Simon Wong, Afsaneh Alavi, Vivian Shi</i>
12:00 - 12:30 pm	Sponsor Exhibit Profiles - visit the booth profile and meet your reps	
12:30-2:12pm	Session 2: Basic & Translational Science Research Foru	<i>Moderator: Simon Wong</i>
Session Learning Objectives		
1. To describe recent data related to the bench research pertaining to HS		
2. To discuss cutting edge translational research findings for HS		
3. To review the perturbations in the microbiome associated with HS		
12:30	Microbiome Research	<i>Amanda Nelson</i>

12:50	Translational Research – From biobank to bench: Understanding immune dysregulation in hidradenitis suppurativa	<i>Angel Byrd</i>
1:10	Drug repurposing for hidradenitis suppurativa treatment	<i>Christos C. Zouboulis</i>
1:18	Immunopathogenesis of HS and Response to Therapy	<i>Margaret M. Lowe</i>
1:26	Localization of Upregulated Proteins in Hidradenitis Suppurativa	<i>Courtney A. Prestwood</i>
1:34	Expression of antimicrobial peptides in lesional keratinocytes of patients with HS	<i>Thomas Meyer</i>
1:42	Live Panel Q&A	<i>All Presenters</i>
3:00pm - 4:00 pm	Accredited Symposium: New approaches based on the latest evidence in HS management All attendees are invited to this accredited symposium	<i>Co-hosted by SHSA and AbbVie Canada</i>

Sunday, October 11		
9:00 am - 10:00 am	Chat Room: Surgery	<i>Moderators: Stephanie Goldberg, Ralph George</i>
9:30 am - 10:00 am	Chat Room: Patient/Caregiver: Conversations with Clinicians	<i>Moderators: Elizabeth O'Brien, Afsaneh Alavi, Iltefat Hamzavi</i>
9:30 am - 10:00 am	Sponsor Exhibit Profiles - visit the booth profile and meet your reps	
10:00-12:00pm	Session 3: Clinical Management	<i>Moderator: Isabelle Delorme</i>
Session Learning Objectives:		
1. To review the treatment of HS, including multimodality treatment		
2. To discuss research related to HS phenotypes		
3. To describe recent data related to the novel HS therapeutics		
10:00	Treatment Combinations	<i>Mark Kirchhoff</i>
10:20	HS Clinical Phenotypes	<i>Hessel van der Zee</i>
10:40	Antibiotherapy targeted against hidradenitis suppurativa flora may significantly improve inflammatory bowel disease symptoms	<i>Aude S. Nassif</i>
10:48	Prevalence and Risk Factors for Anemia in a Population with Hidradenitis Suppurativa	<i>Sydney R. Resnik</i>
10:56	A Randomized, Placebo-Controlled, Phase 2 Study of the Janus Kinase 1 Inhibitor INCB054707 for Patients With Moderate-to-Severe Hidradenitis Suppurativa	<i>Afsaneh Alavi</i>
11:04	A Patient Survey of Pain Management Modalities used in Hidradenitis Suppurativa	<i>Jennifer M. Fernandez</i>
11:12	Diet, supplementation, and topical home remedies in HS: is there an adjunctive role?	<i>Annika S. Silfvast-Kaiser</i>
11:20	The Use of Brodalumab in Hidradenitis Suppurativa: Results from Two Open Label Cohort Studies	<i>John W. Frew</i>
11:28	Live Panel Q&A	<i>All Presenters</i>
12:00 - 12:30 pm	Sponsor Exhibit Profiles - visit the booth profile and meet your reps	
12:00 - 12:30 pm	Chat Room: Patient/Caregiver: Treatment of HS Procedures	<i>Moderators: Ralph George, Elizabeth O'Brien</i>

12:30 - 2:20pm	Session 4: Clinical Study Design and Outcome Measures	Moderator: Stephanie Goldberg
Session Learning Objectives		
1. To discuss research findings for novel HS outcome measures		
2. To describe research pertaining to HS disease states and measurement		
3. To review aspects of clinical trial design for HS		
12:30	The HS-patient decision aid: practical aspects and future directions	<i>Jerry Tan</i>
12:50	The Outcome Measure May Vary By the Drug Mechanism of Action and Immune Mediated Inflammatory Disease Being Treated	<i>Wayne Gulliver</i>
1:10	Evaluating the responsiveness and score bands of the HiSQOL, a novel HS-specific patient-reported outcome measure	<i>Joslyn S. Kirby</i>
1:18	Novel approach to HS flare measurement using patient-reported outcomes	<i>Joslyn S. Kirby</i>
1:26	Quantifying the Natural Variation in Lesion Counts Over Time in Untreated Hidradenitis Suppurativa: Implications for Outcome Measures and Trial Design	<i>John W. Frew</i>
1:34	Do HS trial participants reflect the HS patient population?	<i>Victoria M. Madray</i>
1:42	Development and validation of an Investigator Global Assessment in HS	<i>Amit Garg</i>
1:50	Live Panel Q&A	<i>All presenters</i>
2:20pm - 2:35pm	Session: Closing Remarks	<i>Joslyn Kirby, Isabelle Delorme, Iltefat Hamzavi</i>
	Patient Perspective Closing Remarks	<i>Sandra Guilbault</i>
2:30 - 3:00pm	Sponsor Exhibit Profiles - visit the booth profile and meet your reps	
2:30 - 3:00pm	Chat Room: Patient/Caregiver: Thanks for attending	Moderators: <i>Michelle Lowes, Joslyn Kirby</i>



Poster Listing

Poster	Title	Presenting Author
P1 – Basic and Translational Research		
P1.01	Molecular Disease Signatures of Hidradenitis Suppurativa Derived from High-throughput RNA Sequencing	Christopher Sayed
P1.02	Combined Transcriptomic and Immunohistochemical Analysis Unveils IL-17 Pathway Engagement in Hidradenitis Suppurativa Lesions	Christian Loesche
P1.03	Epithelialized Tunnels Drive Inflammation in Hidradenitis Suppurativa	Kristina Navrazhina
P1.04	Hidradenitis Suppurativa and Comorbid Disorders: an Immunohistochemical Real-world Approach	Katarzyna P. Kaleta
P1.05	3D-SeboSkin Model for Human ex vivo Studies of Hidradenitis Suppurativa	Xiaoxiao Hou
P1.06	Complement Activation and C5aR1 Elevation in Hidradenitis Suppurativa Patient Lesions	Chris Li
P1.07	Improving Understanding of Hidradenitis Suppurativa Through Deep Clinical Phenotyping and Molecular Profiling	Samuel DePrimo
P2 – Clinical Research		
P2.01	Intravenous Ertapenem for Refractory Hidradenitis Suppurativa	Kayla M. Babbush
P2.02	Physical Flare Symptoms in Hidradenitis Suppurativa	Jennifer M. Fernandez
P2.03	Intralesional Anti-Biofilm Therapy for Acute Tunnels in Patients with Hidradenitis Suppurativa	Maximillian A. Weigelt
P2.04	Characterizing Perimenstrual Flares of Hidradenitis Suppurativa	Erin K. Collier
P2.05	Anti-androgen Therapy in HS: Finasteride as an Alternative to Spironolactone	Kayla M. Babbush
P2.06	Patient Perspectives on Telemedicine for Hidradenitis Suppurativa	Tyler M. Andriano
P2.07	Isotretinoin Therapy in the Treatment of Hidradenitis Suppurativa	Kristen P. Pacific
P2.08	Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa	Elena Gonzalez Brant
P2.09	Study Design and Baseline Characteristics of Phase 3 Studies of Secukinumab (SUNSHINE and SUNRISE) in Patients with Moderate-to-Severe Hidradenitis Suppurativa	Alexa B. Kimball
P2.10	Trial Management During the COVID-19 Pandemic: Lessons Learned from Phase 3 Extension Study of Secukinumab in Patients with Moderate-to-Severe Hidradenitis Suppurativa	Alexa B. Kimball
P2.11	Excellent Response to Treatment in Hidradenitis Suppurativa Patient Treated with Guselkumab	Susanne Gulliver
P2.12	The Characterization of Hidradenitis Suppurativa as Defined by Differences in Age Groups	Maria del Mar Melendez Gonzalez
P2.13	Evaluation of Analytical and Clinical Validity of Doppler Ultrasound-Based Biomarkers in Hidradenitis Suppurativa	David Grand
P2.14	Dermal Tunnels Influence Time to Clinical Response and Family History Influences Time to Loss of Clinical Response in Adalimumab-Treated Hidradenitis Suppurativa	John W. Frew
P2.15	Preliminary Clinical Experience with a Novel Acrylic Film Dressing for Hidradenitis Suppurativa Wounds	Maximillian A. Weigelt
P2.16	Anti-TNF Antibodies in Hidradenitis Suppurativa: a Systematic Review	Justin D. Lu
P2.17	Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): Revised Tool and Psychometric Assessment	Noah I. Goldfarb
P2.18	Clinical Predictors of Pain Severity in Hidradenitis Suppurativa	Mark Jedrzejczak
P2.19	Bridging the Diversity Gap: an Examination of African American Participation in Hidradenitis Suppurativa Clinical Trials	Chidubem A. Okeke
P2.20	Evaluate Cutaneous and Circulating Inflammatory Biomarkers for a Novel IRAK4-Targeted Therapeutic in Hidradenitis Suppurativa	Afsaneh Alavi
P3 – Comorbidities and Complications		
P3.01	Hidradenitis Suppurativa and Down Syndrome: a Systematic Review and Meta-analysis	Megan Lam
P3.02	Hidradenitis Suppurativa and Chromosomal Abnormalities	Monica Shah



Poster	Title	Presenting Author
P3.03	Incidence, Prevalence and Predictors of Inflammatory Arthritis in Patients with Hidradenitis Suppurativa: A Systematic Review and Meta-analysis	Nardin Hanna
P3.04	Squamous Cell Carcinoma Arising in Hidradenitis Suppurativa: A Case Series	Sepideh Ashrafzadeh
P3.05	Hidradenitis Suppurativa and Major Adverse Cardiac Events: A Systematic Review and Meta-Analysis	Heido O. Li
P3.06	Association of Hidradenitis Suppurativa with Inflammatory Arthritis: a Systematic Review and Meta-analysis	Nouf Almuhanna
P3.07	Ustekinumab Induced Myositis: a Case Series	Nneamaka C. Ezekwe
P4 – Epidemiology and Health Services Research		
P4.01	Hidradenitis Suppurativa (Acne Inversa): A Bibliometric Analysis	Surav M. Sakya
P4.02	Access to Surgical Interventions for Hidradenitis Suppurativa	Alexandra Finstad
P4.03	Hidradenitis Suppurativa and Socioeconomic Status: A Systematic Review and Meta-Analysis	Heido O. Li
P4.04	Characterizing a Cohort of Hidradenitis Suppurativa Patients with Developmental and Intellectual Disorders	Avigdor Nosrati
P4.05	British Association of Dermatologists (BAD) National Audit on the management of Hidradenitis Suppurativa (HS)	Samar B. Hasan
P4.06	Hidradenitis Suppurativa in East and Southeast Asian Populations: A Systematic Review and Meta-Analysis	Ryan Goetsman
P4.07	Patient Perspectives on COVID-19 and Hidradenitis Suppurativa in Spring 2020	Kyla N. Price
P4.08	Patients' Experience With Hidradenitis Suppurativa Care and Treatment: Results from the Hidradenitis Suppurativa Patient Experience Survey	Rachael Manion
P4.09	Unmet Needs and Struggles With HS From the Patient Perspective	Heather Lapidus Glassner
P4.10	The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa	John W. Frew
P4.11	Trends in The Management of Hidradenitis Suppurativa in The Middle East Region: a Systematic Review	Mehran Karvar
P4.12	Hidradenitis Suppurativa Impact on Parents: a Claims-based Study of Parents of Adolescents with HS	Jay Yang
P4.13	Characterization of Pediatric Patients with Hidradenitis Suppurativa and Implications for Development of Clinical Trials Eligibility Criteria	Helen Bui
P4.14	Social Determinants of Health impacts for People with Hidradenitis Suppurativa	Ankita Sinharoy
P4.15	Expert Management of HS Pain: a Survey Study	Mark Jedrzejczak
P4.16	Delay in Diagnosis, Severity of Disease, and Dermatology Visits in Black and White Hidradenitis Suppurativa Patients in Southeast Wisconsin	Gretchen M. Roth
P5 – Therapy Including Surgical, Medical, and Complementary		
P5.01	Use of Infliximab vs. Infliximab-abda in Patients with Hidradenitis Suppurativa	Linnea L. Westerkam
P5.02	Surgical Management of Hurley Grade III Hidradenitis Suppurativa Using ECM Graft	Abigail Chaffin
P5.03	Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous Tumor Necrosis Factor-alpha Treatment Failure	Maria del Mar Melendez Gonzalez
P5.04	A Retrospective Analysis of the Duration of Long-Term Oral Antibiotic Use for the Treatment of Hidradenitis Suppurativa	Sarah Kitts
P5.05	Systemic Steroids May Reveal or Worsen Hidradenitis Suppurativa	Aude S. Nassif
P5.07	The Use of Biologics in Pediatric Patients with Hidradenitis Suppurativa: a Systematic Review	Muskaan Sachdeva
P5.08	Hidradenitis Suppurativa in Female-to-male Transgender Patients after Initiation of Testosterone Therapy	Michelle Buonomo